The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes CareHILGENFELD, Rolf; SEIPKE, Gerhard; BERCHTOLD, Harald et al.Drugs (Basel). 2014, Vol 74, Num 8, pp 911-927, issn 0012-6667, 17 p.Article

Preoperative Hypoglycemia in a Patient Receiving Insulin DetemirOLSON, Ronald P; ANGELYN BETHEL, M; LIEN, Lillian et al.Anesthesia and analgesia. 2009, Vol 108, Num 6, pp 1836-1838, issn 0003-2999, 3 p.Article

Defining the Role of Insulin Detemir in Basal Insulin TherapyMORALES, Javier.Drugs (Basel). 2007, Vol 67, Num 17, pp 2557-2584, issn 0012-6667, 28 p.Article

Pas de lien formel entre insulîne glargine et cancerBABAI, Samy; BROCVIELLE, Hélène; LE LOUET, Hervé et al.Médecine (Montrouge). 2009, Vol 5, Num 9, issn 1777-2044, p. 399Article

Effect of insulin detemir, compared to human insulin, on 3T3-L1 adipogenesisBÖHM, Anja; STAIGER, Harald; HENNIGE, Anita M et al.Regulatory peptides. 2008, Vol 151, Num 1-3, pp 160-163, issn 0167-0115, 4 p.Article

Elderly Patients with Diabetes Experience a Lower Rate of Nocturnal Hypoglycaemia with Insulin Degludec than with Insulin Glargine: A Meta-Analysis of Phase IIIa TrialsSORLI, Christopher; WARREN, Mark; OYER, David et al.Drugs & aging. 2013, Vol 30, Num 12, pp 1009-1018, issn 1170-229X, 10 p.Article

Insulin detemir is not transported across the blood-brain barrierBANKS, William A; MORLEY, John E; LYNCH, Jessica L et al.Peptides (New York, NY. 1980). 2010, Vol 31, Num 12, pp 2284-2288, issn 0196-9781, 5 p.Article

A Retrospective Review of Glargine Use in PregnancyHENDERSON, Cassandra E; MACHUPALLI, Surekha; MARCANO-VASQUEZ, Heynelda et al.Journal of reproductive medicine. 2009, Vol 54, Num 4, pp 208-210, issn 0024-7758, 3 p.Article

INSULINE GLARGINE ET CANCER: une tempête dans un verre d'eau ? = INSULIN GLARGINE AND CANCER: A STORM IN A GLASS OF WATER ?SCHEEN, A. J; LEFEBVRE, P. J.RMLG. Revue médicale de Liège. 2009, Vol 64, Num 9, pp 440-445, issn 0370-629X, 6 p.Article

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO) : an open randomised controlled trial. CommentaryKUDVA, Yogish C; MONTORI, Victor M; BRETZEL, Reinhard G et al.Lancet (British edition). 2008, Vol 371, Num 9618, issn 0140-6736, 1073-1084, 1047-1048 [14 p.]Article

Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy SubjectsHENRY, Robert R; MUDALIAR, Sunder; CHEN QUIN LAM, Eric et al.Diabetes care. 2014, Vol 37, Num 9, pp 2609-2615, issn 0149-5992, 7 p.Article

Lantus (insuline glargine) Pas d'avantage clinique par rapport aux autres insulines = Glargine: a modest but significant reduction in the risk of hypoglycemia in type 2 diabetes Fabrice BonnetLa Revue du praticien (Paris). 2012, Vol 62, Num 1, issn 0035-2640, p. S7, SUPArticle

An increased dose of insulin detemir improves glycaemic control and reduces body weight of Japanese patients with diabetesFUJII, H; WATANABE, Y; MIYAKAWA, T et al.International journal of clinical practice (Esher). 2010, Vol 64, Num 11, pp 1512-1519, issn 1368-5031, 8 p.Article

Dose-Response Effects of Insulin Glargine in Type 2 DiabetesZHIHUI WANG; HEDRINGTON, Maka S; GOGITIDZE JOY, Nino et al.Diabetes care. 2010, Vol 33, Num 7, pp 1555-1560, issn 0149-5992, 6 p.Article

Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH InsulinSTÜRMER, Til; ALISON MARQUIS, M; BUSE, John B et al.Diabetes care. 2013, Vol 36, Num 11, pp 3517-3525, issn 0149-5992, 9 p.Article

Metabolism of Insulin Glargine After Repeated Daily Subcutaneous Injections in Subjects With Type 2 DiabetesLUCIDI, Paola; PORCELLATI, Francesca; ROSSETTI, Paolo et al.Diabetes care. 2012, Vol 35, Num 12, pp 2647-2649, issn 0149-5992, 3 p.Article

Risque de cancers chez des patients diabétiques traités par insuline glargine ? = Risk of malignancies in patients with diabetes treated with insulin glargineLa Revue Prescrire. 2010, Vol 30, Num 318, pp 268-270, issn 0247-7750, 3 p.Article

The Alteration of Aspart Insulin Pharmacodynamics When Mixed With Detemir InsulinCENGIZ, Eda; SWAN, Karena L; TAMBORLANE, William V et al.Diabetes care. 2012, Vol 35, Num 4, pp 690-692, issn 0149-5992, 3 p.Article

Insulin Detemir: A Review of its Use in the Management of Diabetes MellitusKEATING, Gillian M.Drugs (Basel). 2012, Vol 72, Num 17, pp 2255-2287, issn 0012-6667, 33 p.Article

Desensitization of allergy to human insulin and its analogs by administering insulin aspart and insulin glarginePING WU; CHENG JI; MINGLI WANG et al.Annales d'endocrinologie. 2013, Vol 74, Num 1, pp 56-58, issn 0003-4266, 3 p.Article

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine: A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)RIDDLE, Matthew C; FORST, Thomas; ARONSON, Ronnie et al.Diabetes care. 2013, Vol 36, Num 9, pp 2497-2503, issn 0149-5992, 7 p.Article

Insulin Glargine Safety in Pregnancy: A transplacental transfer studyPOLLEX, Erika K; FEIG, Denice S; LUBETSKY, Angelika et al.Diabetes care. 2010, Vol 33, Num 1, pp 29-33, issn 0149-5992, 5 p.Article

Analogues et dosages d'insuline: le cas général et le cas particulier de la glargine = Analogues and insulin assays: In the main and glargine special caseAGIN, A; SAPIN, R.Médecine nucléaire (Paris). 2010, Vol 34, Num 10, pp 571-582, issn 0928-1258, 12 p.Conference Paper

Insulin analogues : Action profiles beyond glycaemic controlECKARDT, Kristin; ECKEL, Jürgen.Archives of physiology and biochemistry. 2008, Vol 114, Num 1, pp 45-53, issn 1381-3455, 9 p.Conference Paper

Addition of exenatide BID to insulin glargine: a post-hoc analysis of the effect on glycemia and weight across a range of insulin titrationBUSE, John B; HAN, Jenny; MILLER, Stephan et al.Current medical research and opinion. 2014, Vol 30, Num 7, pp 1209-1218, issn 0300-7995, 10 p.Article